PURPOSE: Pemetrexed is a recognized active agent for the second-line treatment for advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the clinical benefits of pemetrexed and to identify patient characteristics that predict response to pemetrexed. METHODS: We retrospectively reviewed the medical records of patients with histologically proven stage IIIB or IV NSCLC who were treated with pemetrexed after the failure of prior chemotherapy. RESULTS: The objective response rate for the 99 enrolled patients was 13.1% and 22 patients achieved stable disease (SD)-a disease control rate of 35.4%. Progression-free survival and overall survival (OS) were 1.8 months (95% CI, 1.32-2.28) and 7.6 months (95% CI, 6.23-8.97), respectively. The patients who achieved SD and pemetrexed-responders showed similar OSs (14.6 vs. 14.8 months, P = 0.55). However, a squamous cell carcinoma histology showed no significant OS difference between those that achieved disease control or progression (8.1 vs. 5.6 months, P = 0.07). Subgroup analysis of OS revealed that histology and response to first-line therapy predicted response to pemetrexed. CONCLUSIONS: Pemetrexed has comparable survival benefits in NSCLC patients that show objective response or stable disease.
PURPOSE:Pemetrexed is a recognized active agent for the second-line treatment for advanced non-small cell lung cancer (NSCLC). This study was undertaken to evaluate the clinical benefits of pemetrexed and to identify patient characteristics that predict response to pemetrexed. METHODS: We retrospectively reviewed the medical records of patients with histologically proven stage IIIB or IV NSCLC who were treated with pemetrexed after the failure of prior chemotherapy. RESULTS: The objective response rate for the 99 enrolled patients was 13.1% and 22 patients achieved stable disease (SD)-a disease control rate of 35.4%. Progression-free survival and overall survival (OS) were 1.8 months (95% CI, 1.32-2.28) and 7.6 months (95% CI, 6.23-8.97), respectively. The patients who achieved SD and pemetrexed-responders showed similar OSs (14.6 vs. 14.8 months, P = 0.55). However, a squamous cell carcinoma histology showed no significant OS difference between those that achieved disease control or progression (8.1 vs. 5.6 months, P = 0.07). Subgroup analysis of OS revealed that histology and response to first-line therapy predicted response to pemetrexed. CONCLUSIONS:Pemetrexed has comparable survival benefits in NSCLCpatients that show objective response or stable disease.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Paolo Ceppi; Marco Volante; Silvia Saviozzi; Ida Rapa; Silvia Novello; Alberto Cambieri; Marco Lo Iacono; Susanna Cappia; Mauro Papotti; Giorgio V Scagliotti Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: G J Weiss; R Rosell; F Fossella; M Perry; R Stahel; F Barata; B Nguyen; S Paul; P McAndrews; N Hanna; K Kelly; P A Bunn Journal: Ann Oncol Date: 2007-03 Impact factor: 32.976
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Jennifer Sigmond; Harold H J Backus; Dorine Wouters; Olaf H Temmink; Gerrit Jansen; Godefridus J Peters Journal: Biochem Pharmacol Date: 2003-08-01 Impact factor: 5.858
Authors: Luiz Henrique de Lima Araújo; Marcos Veloso Moitinho; Ana Maria Fantini Silva; Cleudes Alice Sousa Gomes; Hélio Noronha Júnior Journal: Med Oncol Date: 2010-12-31 Impact factor: 3.064